TG Therapeutics enters into collaboration to develop and commercialize Novel BET Inhibitor
TG Therapeutics announced that as part of a broader agreement with Jubilant Biosys, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. May 27, 2016